Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
February 28, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics to Participate in Upcoming Investor Conferences
February 09, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 24, 2023 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases
January 09, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
- Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial...
Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
December 14, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2022 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
November 08, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
- Voyager’s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs...
Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
November 01, 2022 07:30 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2022 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...